机译:由于严重的蛋白尿,从Lenvatinib从Lenvatinib从Lenvatinib到索拉非尼的患者的成功治疗切换到患有放射性碘 - 难治的甲状腺癌的甲状腺癌
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Department of Otolaryngology-Head and Neck Surgery Kobe University Graduate School of Medicine;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Department of Otolaryngology-Head and Neck Surgery Kobe University Graduate School of Medicine;
Department of Internal Medicine Kuma Hospital;
Department of Surgery Kuma Hospital;
Department of Surgery Kuma Hospital;
Department of Diagnostic Pathology Kuma Hospital;
Department of Surgery Kuma Hospital;
Division of Medical Oncology/Hematology Department of Medicine Kobe University Graduate School of;
Radioactive iodine-refractory differentiated thyroid cancer; Lenvatinib; Sorafenib; Proteinuria; Renal impairment;
机译:由于严重的蛋白尿,从Lenvatinib从Lenvatinib从Lenvatinib到索拉非尼的患者的成功治疗切换到患有放射性碘 - 难治的甲状腺癌的甲状腺癌
机译:Lenvatinib的真实疗效和安全性:来自富于富含放射性碘 - 难治分化的甲状腺癌患者的富有同情心使用的数据
机译:Lenvatinib诱导的放射性碘难治性乳头状甲状腺癌引起的血栓性微血管病合并严重蛋白尿。
机译:放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
机译:索拉非尼和Lenvatinib治疗放射性碘 - 难治性分化甲状腺癌的转移/复发
机译:用Lenvatinib处理的放射性碘 - 难治性分化分化的甲状腺癌多峰寄生。